Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV‐III antibodies to recombinant α‐interferon

In a randomized controlled trial, 41 chronic hepatitis B virus carriers were allocated, by opening numbered computerized randomization envelopes, to receive recombinant interferon‐α2A at three different doses: 2.5; 5.0, and 10.0 mU per m2. Thirty‐two patients received treatment (6 for 3 months, 26 for 6 months), and 9 patients were controls (received no treatment). Ninety‐three per cent of our patients were homosexual, and 41% had anti‐HTLV‐III in their serum

[1]  P. Karayiannis,et al.  Lymphoblastoid interferon therapy of chronic HBV infection. A comparison of 12 vs. 24 weeks of thrice weekly treatment. , 1987, Journal of hepatology.

[2]  H. Thomas,et al.  Homology between HBV‐DNA and a sequence regulating the interferon‐induced antiviral system: Possible mechanism of persistent infection , 1986, Journal of medical virology.

[3]  H. Thomas,et al.  HLA class I antigens on the hepatocyte membrane during recovery from acute hepatitis B virus infection and during interferon therapy in chronic hepatitis B virus infection , 1986, Hepatology.

[4]  J. Hoofnagle,et al.  Pilot study of recombinant human α-interferon for chronic type B hepatitis , 1986 .

[5]  P. Gregory.  Interferon in chronic hepatitis B. , 1986, Gastroenterology.

[6]  S. Salahuddin,et al.  Isolation of infectious human T-cell leukemia/lymphotropic virus type III (HTLV-III) from patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) and from healthy carriers: a study of risk groups and tissue sources. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[7]  W. Darrow,et al.  Exposure to human T-lymphotropic virus type III/lymphadenopathy-associated virus and immunologic abnormalities in asymptomatic homosexual men. , 1985, Annals of internal medicine.

[8]  A. Mindel,et al.  RISING PREVALENCE OF HUMAN T-LYMPHOTROPIC VIRUS TYPE III (HTLV-III) INFECTION IN HOMOSEXUAL MEN IN LONDON , 1985, The Lancet.

[9]  H. Thomas,et al.  Natural history of chronic hepatitis B virus infection in taiwan: Studies of hepatitis B virus DNA in serum , 1985, Hepatology.

[10]  A. Vaheri,et al.  Immune functions in homosexual men with antibodies to HTLV-III in Finland. , 1985, Clinical and experimental immunology.

[11]  A. Lok,et al.  Detection of serum HBV-DNA by molecular hybridisation. Correlation with HBeAg/anti-HBe status, racial origin, liver histology and hepatocellular carcinoma. , 1985, Journal of hepatology.

[12]  A. Lok,et al.  Diminished responsiveness of homosexual men to antiviral therapy for HBsAg-positive chronic liver disease. , 1985, Journal of hepatology.

[13]  H. Thomas,et al.  Antiviral therapy in hepatitis B infection. , 1985, British medical bulletin.

[14]  E. Gelmann,et al.  Hepatitis B virus infection in the acquired immunodeficiency syndrome. , 1984, Annals of internal medicine.

[15]  T. Merigan,et al.  Acute Dane particle suppression with recombinant leukocyte A interferon in chronic hepatitis B virus infection. , 1983, The Journal of infectious diseases.

[16]  H. Thomas,et al.  Hepatitis B Virus and HLA Antigen Display in the Liver During Chronic Hepatitis B Virus Infection , 2007, Hepatology.

[17]  A. Goodall,et al.  A rapid one-step radiometric assay for hepatitis B surface antigen utilizing monoclonal antibodies. , 1982, Journal of immunological methods.

[18]  E. Borden,et al.  Leukocyte-derived interferon (alpha) in human breast carcinoma. The American Cancer Society phase II trial. , 1982, Annals of internal medicine.

[19]  H. Thomas,et al.  The detection of hbv‐dna in serum by molecular hybridisation: A more sensitive method for the detection of complete hbv particles , 1982, Journal of medical virology.

[20]  P. Lengyel.  Biochemistry of interferons and their actions. , 1982, Annual review of biochemistry.

[21]  Lu-Yu Hwang,et al.  HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS A Prospective Study of 22 707 Men in Taiwan , 1981, The Lancet.

[22]  I. Murray-Lyon,et al.  NATURAL HISTORY OF LIVER DISEASE IN CHRONIC HEPATITIS B SURFACE ANTIGEN CARRIERS Survey of 100 Patients from Great Britain , 1981, The Lancet.

[23]  P. Hokland,et al.  Interferon enhances the antibody-dependent cellular cytotoxicity (ADCC) of human polymorphonuclear leukocytes. , 1981, Journal of immunology.

[24]  J. Hoofnagle,et al.  Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. , 1981, Annals of internal medicine.

[25]  T. Merigan,et al.  Antiviral treatment of chronic hepatitis B virus infection. I. Changes in viral markers with interferon combined with adenine arabinoside. , 1981, The Journal of infectious diseases.

[26]  T. Merigan,et al.  Antiviral treatment of chronic hepatitis B virus infection: Improvement in liver disease with interferon and adenine arabinoside , 1981, Hepatology.

[27]  P. Hokland,et al.  Interferon‐induced Augmentation of Cytotoxic Killer Cell Generation in Mixed Lymphocyte Cultures: Analysis of the Effector Cell Product , 1981, Scandinavian journal of immunology.

[28]  D. Campbell,et al.  Spontaneous cytotoxicity mediated by human monocyte-macrophages against human fibroblasts infected with herpes simplex virsu--augmentation by interferon. , 1980, Cellular immunology.

[29]  R. Friedman,et al.  Double-stranded RNA inhibits a phosphoprotein phosphatase present in interferon-treated cells. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[30]  P. Keeling,et al.  LIVER DISEASE AMONG HOMOSEXUAL MALES , 1979, The Lancet.

[31]  R. Truhaut,et al.  HUMAN CARCINOGENESIS , 1976, The Lancet.

[32]  R. Verwilghen,et al.  DANGERS OF PETROL USED AS SOLVENT , 1975, The Lancet.

[33]  F. R. Zadik.  FRACTURE OF THE FEMORAL NECK. , 1964, Lancet.

[34]  R. Good,et al.  Fatal complications of virus hepatitis in two patients with agammaglobulinemia. , 1960, The American journal of medicine.